| 000 | 00956 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250517090710.0 | ||
| 264 | 0 | _c20161223 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1468-960X | ||
| 024 | 7 |
_a10.1136/eb-2015-102143 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCitrome, Leslie | |
| 245 | 0 | 0 |
_aWhich role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? _h[electronic resource] |
| 260 |
_bEvidence-based mental health _c05 2016 |
||
| 300 |
_ae6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 |
_aAntipsychotic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aDopamine _xtherapeutic use |
| 650 | 0 | 4 |
_aDopamine Agonists _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aSchizophrenia _xdrug therapy |
| 773 | 0 |
_tEvidence-based mental health _gvol. 19 _gno. 2 _gp. e6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/eb-2015-102143 _zAvailable from publisher's website |
| 999 |
_c25896976 _d25896976 |
||